Europe

Molecular Health (MH), a leading company in the field of data science for precision medicine, today announced that the Company has signed up the HudsonAlpha Institute for Biotechnology (HudsonAlpha) as a new client for MH Guide.

Biom’up SA, specializing in surgical hemostasis, announced a change in the Company’s leadership position.

Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.

During the full presentation of the abstract on Friday, Janssen will show that treatment with Erleada significantly improved rPFS with a reduction in the risk of death by 52%. Additionally, in overall survival, the TITAN data showed Erleada and ADT significantly improved OS with a 33% reduction in risk of death.

Biopharma companies from across the globe holster their leadership with new appointments.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Novartis’s QMF149 met its primary and key secondary endpoints in the Phase III QUARTZ clinical trial for asthma. QMF149 is a once-daily, fixed-dose combination therapy containing indacaterol acetate, a long-acting beta agonist, and mometasone furoate, an anti-inflammatory.

Orchard Therapeutics, Fondazione Telethon and Ospedale San Raffaele announced that Orchard has been granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the ex vivo autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of Mucopolysaccharidosis Type I (MPS-I) developed by the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

A two-year old patient at the Royal Manchester Children’s Hospital (RMCH) is the first in the world to receive a pioneering new ex vivogene therapy treatment using lentiviral vector-modified autologous stem cells for the rare and life-limiting genetic condition, Mucopolysaccharidosis IIIA (MPSIIIA).

Probiodrug AG, announces that its shareholders approved all resolutions proposed by the Company’s Management and Supervisory Board at the Company’s Annual General Meeting which took place on Wednesday, May 29, 2019